AVDL vs. NUVL, AXSM, TGTX, CRSP, MTSR, MRUS, KRYS, PTCT, MENS, and ARWR
Should you be buying Avadel Pharmaceuticals stock or one of its competitors? The main competitors of Avadel Pharmaceuticals include Nuvalent (NUVL), Axsome Therapeutics (AXSM), TG Therapeutics (TGTX), CRISPR Therapeutics (CRSP), Metsera (MTSR), Merus (MRUS), Krystal Biotech (KRYS), PTC Therapeutics (PTCT), Jyong Biotech (MENS), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry.
Avadel Pharmaceuticals vs. Its Competitors
Nuvalent (NASDAQ:NUVL) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.
Nuvalent has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500.
In the previous week, Nuvalent had 5 more articles in the media than Avadel Pharmaceuticals. MarketBeat recorded 7 mentions for Nuvalent and 2 mentions for Avadel Pharmaceuticals. Nuvalent's average media sentiment score of 0.64 beat Avadel Pharmaceuticals' score of 0.21 indicating that Nuvalent is being referred to more favorably in the media.
97.3% of Nuvalent shares are held by institutional investors. Comparatively, 69.2% of Avadel Pharmaceuticals shares are held by institutional investors. 10.2% of Nuvalent shares are held by insiders. Comparatively, 5.2% of Avadel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Avadel Pharmaceuticals has higher revenue and earnings than Nuvalent. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.
Nuvalent has a net margin of 0.00% compared to Avadel Pharmaceuticals' net margin of -1.32%. Avadel Pharmaceuticals' return on equity of -3.73% beat Nuvalent's return on equity.
Nuvalent presently has a consensus price target of $118.89, suggesting a potential upside of 43.47%. Avadel Pharmaceuticals has a consensus price target of $20.86, suggesting a potential upside of 44.99%. Given Avadel Pharmaceuticals' higher probable upside, analysts plainly believe Avadel Pharmaceuticals is more favorable than Nuvalent.
Summary
Nuvalent and Avadel Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.
Get Avadel Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AVDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avadel Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:AVDL) was last updated on 10/7/2025 by MarketBeat.com Staff
